It’s been a rough year to be a biotech investor. The market-cap-weighted iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) is down about 25% so far this year.
It’s been a rough year to be a biotech investor. The market-cap-weighted iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) is down about 25% so far this year.